The effect of interstitial pressure on therapeutic agent transport: Coupling with the tumor blood and lymphatic vascular systems
Introduction
Chemotherapy is a type of cancer treatment that targets cancer cells through the use of toxic agents, primarily drug molecules disrupting some aspect of cell division, such as DNA synthesis and function. Ideally, drug dosages should be sufficient to kill rapidly dividing tumor cells but not affect non-cancerous cells. Although isolated infusion is sometimes used to deliver a concentrated dosage more directly to specific tumor sites (Chreech et al., 1958, Noorda et al., 2007, McClaine et al., 2012), most drugs are delivered systemically as an oral or intravenous bolus. Tissues in the body that undergo cell proliferation under normal circumstances, such as cells in the digestive system, are also typically damaged by chemotherapeutic drugs. Consequently, the drug dose is usually the maximum tolerated dose (MTD) that prevents patient death but may be well below what is needed to eradicate all of the tumor cells. Diverse macromolecule agents (e.g., nanoparticle carriers as summarized in Jong and Borm, 2008) have been developed as vehicles to encapsulate drugs in order to achieve higher targeting efficacy while minimizing systemic toxicity. Nevertheless, both free drug and nanoparticles administered systematically suffer from impaired transport through tumor tissue due to the abnormal vascularization. Further, dosing schemes are crucial since the tumor response depends not only on the dynamics of the agents and the fluids that carry them but also on the complex physiology of the body systems and the local tumor tissue. Recent theoretical studies with the aid of mathematical modeling and computational simulation, coupled with the latest experimental technologies (e.g., intravital microscopy), have highlighted the complexity of chemotherapy delivery and uptake in live tumors (van de Ven et al., 2012, van de Ven et al., 2013).
Theoretical modeling of chemotherapy usually relies on partial differential equation (PDEs) to describe the transport dynamics as well as the pharmacokinetics of therapeutic agents in time and space. Beginning with the vasculature, most studies have focused on the interaction between the vascular structure and blood flow, which contributes to the transport characteristics and agent availability through the vascular network as a closed system (e.g., McDougall et al., 2002, Stephanou et al., 2005, McDougall et al., 2006, Bartha and Rieger, 2006, Lee et al., 2006, Welter et al., 2008, Welter et al., 2009, Welter et al., 2010). However, fluids and substrates are exchanged through the vascular wall in the capillary regions. In the tumor interstitium, transport subject to interstitial fluid flow (IFF) has been investigated, where barriers due to lymphatic dysfunction as well as other common tumor pathologies (e.g., elevated vascular hydraulic conductivity and resultant attenuated transvascular osmotic pressure) were studied theoretically by Baxter and Jain, 1989, Baxter and Jain, 1990. These authors modeled the source of fluids and substrates through a vascular continuum and the effect of vascular flow was not considered. Recently, IFP, IFF and vascularized tumor growth were coupled dynamically in computational models by Cai et al. (2011), Wu et al. (2013), and Welter and Rieger (2013).
Pharmacokinetics and pharmacodynamics (PKPD) models, which combine reaction-diffusion PDEs that model the transport of chemotherapy agents in the tissue, and mass-action ordinary differential equations (ODEs) that model biochemical reactions in the cells, have been used to predict the tumor response to certain types of drug molecules (e.g., doxorubicin and cisplatin, see Jackson, 2003; Sanga et al., 2006, and Sinek et al., 2009), or to predict agent availability due to innovative transport modalities (e.g., nanoparticles or macrophages loaded with nanoparticles, see Sinek et al., 2004, Owen et al., 2004, respectively), as well as the resulting tumor response and therapy limitations (Frieboes et al., 2009, Sinek et al., 2009). Although most of these efforts are tied to angiogenesis models as the source of the agents, the extravasation is often assumed to be affected only by the transvascular concentration difference and the physical pressure from tumor cells outside the vasculature. The effects of convective transport by the interstitial fluid are usually not considered or are coupled with the tumor cell velocity (e.g., Jackson, 2003) instead of the IFF which can carry the agents through the interstitium.
Very recently, interstitial fluid flow and drug delivery have been investigated by Welter and Rieger (2013) in a 3-dimensional vascular tumor growth model using a continuum model for tumor cells and an arteriole-venous vascular network that accounted for drainage of interstitial fluid due to lymphatic function. Welter and Rieger (2013) found that the IFP, the IFF and the drug distributions are strongly heterogeneous due to the vascular architecture.
Here, we study the transport of therapeutic agents in a 2-dimensional interstitial continuum covered by a discrete tumor vasculature initially laid out as a rectangular grid to simulate the pre-existing capillary network. Unlike (Welter and Rieger, 2013) where the arterio-venous system is explicitly built, the capillaries considered here serve as both arterial and venous conduits since they are the smallest blood-carrying units in the tissue. Our approach builds on the tumor growth model developed in Macklin et al. (2009) and Wu et al. (2013), where we investigated the transcapillary and interstitial fluid dynamics during vascularized tumor growth coupled with the effect of blood and lymphatic vessel collapse. In particular, we investigated the effect of tumor vascular pathologies on the fluid flow across the tumor capillary bed, the lymphatic drainage and the IFP. Here, we focus on how the pathologies affect the transport of therapeutic agents during chemotherapy and the response of the tumor through the fluid flow. Considering the concentration of chemotherapy agents both in the vasculature and in the interstitium linked by the transcapillary fluid flux (modeled in Wu et al., 2013), as well as the loss of agents into the lymphatic system through the lymphatic fluid drainage (modeled in Wu et al., 2013), the model presented here can adapt to diverse delivery scenarios according to the specific agent characteristics and delivery protocols. In particular, we apply the model to study two injection schemes. The first, called “bolus injection,” applies to agents injected upstream of the tumor vasculature for a short period of time (e.g., 1–10 min). The second scheme, called “constant injection,” applies to agents injected upstream for a prolonged period of time (~100 min). We study the temporal and spatial distribution of agents in the vasculature and the interstitium together with the transcapillary concentration flux. We evaluate the efficiency of agent delivery while varying the functional lymphatic distribution and associated pathological factors. Finally, we assess the effects of chemotherapy on a growing tumor.
The outline of the paper is as follows. We present the mathematical models in Section 2, and describe the numerical details in Section 3. We present the results in Section 4, followed by a discussion in Section 5, in which the conclusion and future work are also described.
Section snippets
The coupled mathematical model
We review the agent transport model that is applied to the vascular tumor growth model described in Wu et al. (2013). For completeness, the modeling of vascular and interstitial fluid dynamics from Wu et al. (2013) is briefly described in Section 2.1. In Section 2.2 we consider the tumor progression under the influence of therapeutic agents where we describe the agent transport in the vasculature and in the interstitium by two reaction-convection-diffusion equations coupled by the
Numerical details
Briefly, following Wu et al. (2013) we discretize the elliptic/parabolic equations (6), (10), (19) in space using centered finite difference approximations and the backward Euler time-stepping algorithm. The discrete equations are solved using a nonlinear adaptive Gauss–Seidel iterative method (NAGSI) (Macklin and Lowengrub, 2007, Macklin and Lowengrub, 2008). We use a first order upwind discretization of the advection term explicitly in time. The time step is chosen to satisfy the CFL
Simulation and parameter studies
We first consider two representative injection schemes and evaluate the agent delivery under varying conditions in Section 4.1. We show the effect of pathological factors on the agent distribution and delivery characteristics in Section 4.2. We simulate chemotherapy and discuss the effect of pathological factors on tumor response in Section 4.3. The parameters used in these studies are given in Table 1.
As described in our previous work (Wu et al., 2013), a uniform pre-existing vascular network
Discussion
In this study we employed mathematical modeling and simulation to quantitatively evaluate the role of hypertensive IFP and associated pathological conditions on the delivery of chemotherapeutic agents to vascularized tumors and on the tumor response to these agents. We found that agent extravasation from the bloodstream is hindered by the hypertensive IFP through convection by the transvascular fluid flux. While the agents can be washed away from the tumor into the neighboring host tissue as a
Acknowledgments
H.F. acknowledges funding by NIH/NCI PS-OC Grants U54CA143907 and U54CA143837. V.C. acknowledges funding by the Cullen Trust for Health Care, NIH/NCI PS-OC Grants U54CA143907 and U54CA143837, NIH-ICBP Grant U54CA149196, and NSF Grant DMS-0818104. J.L. acknowledges funding by the NSF, Division of Mathematical Sciences, the NIH Grant P50GM76516 for a Center of Excellence in Systems Biology at the University of California, Irvine, and the NIH Grant P30CA062203 for the Chao Comprehensive Cancer
References (49)
- et al.
Vascular network remodeling via vessel cooption, regression and growth in tumors
J. Theor. Biol.
(2006) - et al.
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Microvasc. Res.
(1989) - et al.
Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics
Microvasc. Res.
(1990) - et al.
Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation
J. Theor. Biol.
(2008) - et al.
Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion
J. Theor. Biol.
(2011) - et al.
Three-dimensional multispecies tumor growth II. Tumor invasion and angiogenesis
J. Theor. Biol.
(2010) Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model
J. Theor. Biol.
(2003)- et al.
Nonlinear simulation of the effect of microenvironment on tumor growth
J. Theor. Biol.
(2007) - et al.
Mathematical modelling of dynamic adaptive tumour-induced angiogenesisclinical implications and therapeutic targeting strategies
J. Theor. Biol.
(2006) - et al.
Mathematical modelling of flow through vascular networksimplications for tumour-induced angiogenesis and chemotherapy strategies
Bull. Math. Biol.
(2002)
The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion
Eur. J. Surg. Oncol.
Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites
J. Theor. Biol.
Mathematical modelling of flow in 2d and 3d vascular networksapplications to anti-angiogenic and chemotherapeutic drug strategies
Math. Comput. Model.
Emergent vascular network inhomogeneities and resulting blood flow patterns in a growing tumor
J. Theor. Biol.
Vascular remodelling of an arterio-venous blood vessel network during solid tumour growth
J. Theor. Biol.
Three-dimensional multispecies nonlinear tumor growth-i model and numerical method
J. Theor. Biol.
The effect of interstitial pressure on tumor growthcoupling with the blood and lymphatic vascular systems
J. Theor. Biol.
Chemotherapy of cancerregional perfusion utilizing an extracorporeal circuit
Ann. Surg.
Intravascular delivery of particulate systemsdoes geometry really matter?
Pharm. Res.
Prediction of drug response in breast cancer using integrative experimental/computational modeling
Cancer Res.
A computational model for predicting nanoparticle accumulation in tumor vasculature
PLoS ONE
BiomechanicsCirculation
Vegf and notch signalingthe yin and yang of angiogenic sprouting
Cell Adhes. Migr.
Microvascular and tissue oxygen distribution
Cardiovasc. Res.
Cited by (90)
Nanobiotechnology-based treatment strategies for malignant relapsed glioma
2023, Journal of Controlled ReleaseMechanotransduction in tumor dynamics modeling
2023, Physics of Life ReviewsPhotodynamic and photothermal therapy using PLGA nanoparticles
2023, Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug DeliveryMulti-dimensional modeling of nanoparticles transportation from capillary bed into the tumor microenvironment
2023, Computers in Biology and MedicineCitation Excerpt :Sefidgar et al. [27,28], with an element-based finite volume method, first investigated the effect of tumor shape, size, and tissue transfer characteristics on drug delivery to solid tumors and then modeled drug delivery in dynamic solid TMV. Wu et al. [29] capitalized on a nonlinear adaptive Gauss-Seidel iterative method and studied the effect of interstitial pressure on therapeutic agent transport in connection with the blood vessels and the lymphatic system. Nabil et al. [30] utilized the finite element method and reported mass and heat transfer modeling in nano-based cancer hyperthermia.
A model of magnetic nanoparticle transport and their effects in tumor areas: Assessment of desirable magnetic properties
2022, Journal of Magnetism and Magnetic MaterialsTherapeutic antibodies – natural and pathological barriers and strategies to overcome them
2022, Pharmacology and Therapeutics
- 1
Joint first authorship.